Implantable construct for architectural control of re-vascularization of ischemic

描述(由申请人提供)：Innolign Biomedical已经开发出一种植入性产品，该产品使用新的组织工程技术，可以在空间上指导血管形成，并将使用该产品治疗缺血状况。这项第一阶段STTR提案的目标是确定使用这种名为微桥的新型模板化生物材料治疗心肌缺血的可行性。超过2000万美国人患有缺血性心脏病，估计每年的成本负担超过600亿美元。尽管血管成形术和搭桥手术在挽救冠脉循环的灌注方面取得了实质性进展，但缺血性心脏病仍然是导致死亡和发病率的主要原因。MicroBridge将作为冠状动脉搭桥手术期间的一个辅助设备，引导微血管系统中的血管重新形成，以再灌流仅靠大动脉搭桥无法达到的缺血区。该产品由可生物降解植入物内的内皮细胞和基质的排列索状网络的预先指定的结构组成。在植入后，MicroBridge的结构模板引导新血管从良好的灌注区快速生长到缺血区。目标1的目的是在心肌缺血的动物模型中测试MicroBridge产品对缺血组织血管形成和再灌流的能力。目标2的目标是确定MicroBridge产品在特定储存条件下的稳定性。这些研究将为进一步开发MicroBridge产品作为治疗心肌缺血的药物奠定基础。

DESCRIPTION (provided by applicant): Innolign Biomedical has developed an implantable product using novel tissue engineering technologies that spatially direct vascularization and will use the product in the treatment of ischemic conditions. The goal of this Phase I STTR proposal is to establish the feasibility of using this novel templated biomaterial, termed MicroBridge, to treat cardiac ischemia. More than 20 million Americans suffer from the ischemic heart disease with an estimated cost burden surpassing $60 billion annually. Despite substantial progress in angioplasty and bypass surgery to rescue perfusion to the coronary circulation, ischemic heart disease remains the leading cause of mortality and morbidity. MicroBridge will serve as an adjunct delivered during coronary artery bypass surgery that would direct vascularization in the microvasculature to reperfuse regions of ischemia not reached by large artery bypass alone. The product consists of pre- specified architectures of networks of aligned cords of endothelial cells and matrix within a biodegradable implant. Upon implantation, the architectural template of MicroBridge guides new vessels to rapidly grow from a well perfused region to an ischemic region. The goal of Aim 1 is to test the capability of the MicroBridge product to vascularize and reperfuse ischemic tissue in an animal model of cardiac ischemia. The goal of Aim 2 is to establish the stability of the MicroBridge product under specific storage conditions. These studies will set the stage for further development of the MicroBridge product as a treatment for cardiac ischemia.